ISRAEL’S MEDICAL ACHIEVEMENTS

Treatment pathway for fatal epilepsy

Dravet syndrome is an epileptic condition with a 15 to 20 percent mortality rate and resistant to current medications. Tel Aviv University researchers have discovered that the DHODH gene is key to triggering such adverse neural activity and that Terflunomide can inhibit it.

FDA prioritizes Alzheimer’s therapy device

I reported previously (see here) on the NeuroAD cranial device from Israel’s Neuronix. It already has European approval and is now being urgently reviewed in the FDA’s Expedited Access Pathway program for breakthrough devices that target vital unmet needs.https://www.medpagetoday.com/neurology/alzheimersdisease/78739

Weizmann Institute battles to conquer cancer

At Israel’s Weizmann Institute there are over 60 research groups focusing on beating cancer and over 40% of the Institute’s life sciences research is cancer-related.